Table 1.
Clinicopathological data.
| Partially vaccinated (n = 16) | Fully vaccinated (n = 13) | p value | |
|---|---|---|---|
| Age | 72 (32–97) | 75 (55–95) | 0.272 |
| Gender (f: m) | 1: 1 | 1: 1.6 | 0.806 |
| Autopsy (partial vs complete) | 1: 2.75 | 1: 1.6 | 0.689 |
| COVID-19 Cause of death according WHOa (n) | 15 (94%) | 12 (92%) | 1.000 |
| Cause of death according autopsy results (condition directly leading to death) | 12 (75%) | 9 (69%) | 1.000 |
| Type of infectionb (failure vs. breakthrough) | n.a. | 1: 4 | |
| Vaccine (n; BT vs. AZ vs. SV) | 11: 4: 0c | 11: 1: 1 | 0.263 |
| PCR nasopharyngeal swab at diagnosis [Ct value] | n.a.d | 22 (13–41) | |
| PCR nasopharyngeal swab at autopsy [Ct value] | 18 (9–30) | 16 (10–40) | 0.974 |
| PCR tissue lowest Ct value [Ct value]e | 21 (14–31) | 21 (17–27) | 0.624 |
| Viral dissemination (n) | 11 (69%) | 5 (38%) | 0.209 |
| Time from last vaccination to positive test SARS-CoV-2 | 10 (1–180) | 140 (28–283) | <0.001 |
| Time from first symptom to death | 10 (1–27) | 11 (2–24) | 0.843 |
| Time from first positive PCR to death | 9 (5–25) | 9 (1–20) | 0.301 |
| Positive SARS-CoV-2 serology - spike (n)f | 4 (80%) | 9 (82%) | 1.000 |
| SARS-CoV-2 serology - nucleocapsid (n)f | 3 (100%) | 5 (45%) | 0.209 |
| SARS-CoV-2 lineage- VOC (n) | 10 (63%) | 13 (100%) | 0.020 |
| IgA-levels [normal: 70–400 mg/dl]f | 171 (136–255) | 98 (58–171) | 0.167 |
| IgG-levels [normal: 700–1600 mg/dl]f | 658 (309–832) | 511 (364–820) | 0.666 |
| Highest CRP [normal: <0.5 mg/dl] | 13 (1–34) | 22 (2–35) | 0.304 |
| Highest procalcitonin [normal: <0.5 ng/ml] | 1 (0–100) | 2 (0–100) | 0.414 |
| Highest Il-6 [normal: <15 pg/ml] | 99 (90–50.000) | 506 (16–50.000) | 0.281 |
| Malignancies (n) | 9 (56%) | 3 (23%) | 0.130 |
| Other comorbidities (n) | 3 (0–6) | 4 (1–7) | 0.047 |
| BMI [kg/m²] | 28 (16–50) | 26 (16–37) | 0.617 |
| Invasive ventilation (n) | 5 (31%) | 5 (38%) | 0.714 |
| Dexamethasone Therapy (n)f | 8 (73%)f | 7 (54%) | 0.423 |
| Acute DAD (n) | 12 (75%) | 9 (69%) | 1.000 |
Aggregated data of main characteristics of partially and fully vaccinated cases (for data of each case see Supplementary Tables 1 and 2). Continuous data are given as median with range in brackets.
Bold values indicate statistical significance p < 0.05.
aSee [Ref.33].
bSee [Ref.7].
cVaccine was unknown in one case.
dCt-values have not been determined by the central laboratory during the first half of the year 2021.
eThe lowest Ct-values were found in lung samples in all cases.